Fiercebiotech
Published November 17, 2026
Lilly signs $5.9B deal with Stipple to unlock oncology targets | Fierce Biotech
Read the full story at Fiercebiotech
By then, the biotech aims to have started multiple early ... Helus' chemically modified psychedelic hits key goals in phase 3 depression trial.
Surfaced by this Google Alert
- Psychedelic biotech